SCHEMBL3820110

SCHEMBL3820110

[CH2]Cc1cnc2ccccc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.52
PDGFRB P09619 2/20 0.50
PDGFRA P16234 2/20 0.50
KDM1A O60341 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
MGAM O43451 1/20 0.46
ALDH1A1 P00352 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RAB9A P51151 2/20 0.44
MAPT P10636 2/20 0.44
NPC1 O15118 1/20 0.44
NFKB1 P19838 1/20 0.44
NFKB2 Q00653 1/20 0.44
RELA Q04206 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
FAAH O00519 2/20 0.44
PDE10A Q9Y233 2/20 0.43
CYP2A6 P11509 1/20 0.43
GLA P06280 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28243569 0.98 CYP1A2 (0.50) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL4817698 0.85 CYP1A2 (0.48) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL3396692 0.83 CYP1A2 (0.55) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL10673413 0.82 CYP1A2 (0.50) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL4811474 0.82 CYP1A2 (0.46) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL4817358 0.80 CYP1A2 (0.44) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL6154350 0.80 KDM1A (0.51) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL5700742 0.80 CYP1A2 (0.52) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL6597946 0.80 CYP1A2 (0.52) CYP1A2PDGFRBPDGFRAKDM1AMAOA
SCHEMBL151560 0.80 CYP1A2 (0.57) CYP1A2PDGFRBPDGFRAKDM1AMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023023513-A9 STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE UNIVERSITY OF MASSACHUSETTS (US) 2023-06-01 WO claimed
WO-2023023513-A1 STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE UNIVERSITY OF MASSACHUSETTS (US) 2023-02-23 WO claimed
CN-106187887-B The preparation method of 4- oxyquinoline -3- formic acid 上海工程技术大学 2018-08-14 CN claimed
CN-105143190-B Substituted naphthyridine and quinoline compounds as MAO inhibitors 达特神经科学(开曼)有限公司 2017-08-18 CN claimed
CN-101565428-B Preparation method of prulifloxacin Chongqing kerui pharmaceutical co ltd 2011-06-29 CN claimed
CN-101565428-A Preparation method of prulifloxacin CHONGQING KERUI PHARMACEUTICAL (CN) 2009-10-28 CN claimed
EP-2091929-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS The European Molecular Biology Laboratory (DE) 2009-08-26 EP claimed
CN-101421257-A Agents that disrupt cellular replication and their use in inhibiting pathological conditions EUROPEAN MOLECULAR BIOLOGY LAB EMBL (DE) 2009-04-29 CN claimed
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US claimed
WO-2007107352-A1 AGENTS THAT DISRUPT CELLULAR REPLICATION AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS THE EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) 2007-09-27 WO claimed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US claimed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP claimed
CN-111278846-B Antimicrobial tetrapeptides 帝斯曼知识产权资产管理有限公司 2023-10-27 CN disclosed
EP-4261830-A1 NOVEL PEPTIDOMIMETIC COMPOUND AND DESIGN Oita University Institute of Advanced Medicine, Inc. (JP) 2023-10-18 EP disclosed
CN-116615423-A Novel peptidomimetic compounds and design 株式会社大分大学先端医学研究所 2023-08-18 CN disclosed
WO-2023023513-A9 STABILIZATION OF OLIGONUCLEOTIDE AND OLIGONUCLEOTIDE-PROTEIN COMPLEX USING ALKYLATED PHOSPHATE UNIVERSITY OF MASSACHUSETTS (US) 2023-06-01 WO disclosed
US-5449785-A Fungicides with triazole groups HOFFMANN-LA ROCHE INC. (US) 1995-09-12 US disclosed
CN-1069976-A Hexanaphthene and tetrahydropyran derivatives HOFFMANN LA ROCHE (CH) 1993-03-17 CN disclosed
EP-0524439-A1 Novel cyclohexane and tetrahydropyran derivatives and antifungal compositions containing these derivatives F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) 1993-01-27 EP disclosed
US-4761419-A ANTILIPEMIC WARNER-LAMBERT COMPANY (US) 1988-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 CYP1A2 583/4885PDGFRB 2207/4885PDGFRA 2360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.